




The 19th International Conference on Pharmaceutical Medicine (ICPM 2018)
 第9回日本製薬医学会年次大会

Main Theme
The Future of Medicines Development

• Date: September 27(Thu)-28(Fri), 2018(ICPM&JPhMed)
 September 29(Sat)-2018(JPhMed)



IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine

THIS ISSUE

1. Introducing the Turkish Working Group on Pharmaceutical Medicine
2. An EL.E.F.I. event on Patient Support Programmes
3. IFAPP followers on LinkedIn
4. Anthony Chan to become National Specialty Director in Ireland
5. Webinar on COVID-19 in Japan
6. A SIMeF publication on COVID-19 and clinical research operations


Introducing the Turkish Working Group on Pharmaceutical Medicine

Turkish Working Group on Pharmaceutical Medicine
 Founded: 2020 www.biyoteknolojikilacilardernegi.org
 President: Zafer Guney - IFAPP Delegate: Ilker Gelisen

The Turkish Association of Pharmaceutical Medicine was founded in 2000 by a group of professionals based in Istanbul. After some initial activities, unfortunately the association was no more active. Last year, thanks to the interest in Pharmaceutical Medicine expressed by both Prof Zafer Guney (President of the Biotechnology Association) and by Prof Ilker Gelisen (former President of the Turkish association), the Turkish Working Group on Pharmaceutical Medicine was re-established, as part of the Biotechnology Society. Members of the Working Group recently came together for the first meeting, made some plans for future activities and reviewed possible tools to increase the awareness of IFAPP among the Turkish medical profession. It was decided to prepare a page devoted to IFAPP in the Biotechnological Drugs Association's website.

IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine



The photo shows the following professionals (from left to right, top down):

- Mevra Al, KTO Karatay University, Faculty of Medicine, Medical Pharmacology Department, Konya
- Dr Arın Tomruk, Gazi University, Faculty of Medicine, Biophysics Department, Ankara
- Dr Refika Yamanel Aşık, Gazi University, Faculty of Medicine, Medical Pharmacology Department, Ankara
- Dr Nihat Bozkurt, Gazi University, Faculty of Medicine, Medical Pharmacology Department, Ankara
- Özgür Bozdağ, OZgurbozdağ Consultancy, Ankara
- Dr M. Ilker Gelisen, Near East University Common Courses Coordination, Nicosia, Turkish Republic of Northern Cyprus
- Prof Dr Zafer Guney, Gazi University, Faculty of Medicine, Medical Pharmacology Department, Ankara

M. Ilker Gelisen

An E.L.E.F.I. event on Patient Support Programmes

The Greek Health System was left in a weakened state after one decade of economic crisis and multiple reforms. Among the people most affected by it are the patients with chronic and rare diseases, which incidentally are the ones who require most protection.

To deal with this situation, any approach consists of two components. The spectrum of the first component should include the needs of the patient associations in relation to the State's perception of rare and chronic diseases and the construction of the health policy around them while focusing particularly on the access to the medicines, among others. The second component of the approach should focus on providing support and education to patients to help them to apply the behavioural changes to manage their disease either by themselves or with the help of a multidisciplinary care team of professionals. Among the benefits of this approach are cost savings for Social Security Institutions and an improvement in the results and the quality of care.




IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine



Summary Report transcribed by the Hellenic Society of Pharmaceutical Medicine (EL.E.F.I.)



High patient collaboration contributes to the improvement in their health status, quality of life, avoidance of indirect costs and an increase in their productivity.

Patient Support Programmes (PSPs), when properly structured and specialized, can secure the proper treatment of patients and serve a social need at a time when patients cannot use their own resources to cover their supportive treatment needs, while social security funds do not provide support services.

The major concerns of the representatives of the Patient Advocacy Groups (PAGs) regarding the PSPs had to do with education on the disease and support on communicating and coaching for the individualization and achievement of therapeutic goals. Great attention was also given to the value of the collection and analysis of epidemiological and clinical data on chronic and serious diseases to monitor the implementation of guidelines in clinical practice.

A point of major concern continues to be the evaluation of PSPs regarding the effectiveness of its practice, its contribution to the quality of life and the achievements of patients' therapeutic goals. Finally, more research and collaboration between scientists, PAGs and stakeholders will lead to the development of RWD/RWE institutional framework based on PSP data using digital tools in compliance with General Data Protection Regulation (GDPR).

Stavros Goulakos, BSc in Environmental Studies
EL.E.F.I. Volunteer Scientific Writer



IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine



IFAPP Follower Community on LinkedIn Gets Sizeable

IFAPP has been present on LinkedIn in form of a listed group since 2013. On that platform we have 614 members (as of 22 January 2021). Its aim is to cultivate exchange of Pharmaceutical Medicine experience and knowledge in a two-way dialogue across the globe. The group page does, however, not allow for sharing of posts, and group membership must be applied for and subsequently approved by the group admin.

In consequence of the latter limitations, the IFAPP Communication Working Group launched a company page in April 2020. The primary aim is to reach out to an unrestricted number of pharmaceutical professionals with not only news from the Federation and its membership but also important scientific papers and shared posts from actors of the broad-spectrum discipline that characterizes Pharmaceutical Medicine.

By 22 January 2021, i.e., within nine months only, the IFAPP company page has reached a followership of 623 colleagues from around the world. The top 10 geographic regions being addressed with IFAPP posts to date are displayed in the figure.

Please be invited to become a follower of the [company page](#) from where you can share information that seems relevant to you, and/or apply for group membership at the [group page](#) from where you can post relevant pharmaceutical medicine news yourself. IFAPP does, however, strictly discourage the posting of advertisements on its group page which seems to be fully in line with the group member expectations.



Figure: Top ten locations of 176 followers of the IFAPP company page on LinkedIn as of 22 January 2021 (total follower number = 623).

Dr. med. Johanna Schenk FFPM GFMD
Member of the IFAPP Communication Working Group



IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine



Anthony Chan MB FRCSI DPM GFMD to become National Specialty Director in Ireland



Born in Hong Kong, Anthony attended boarding school in Canterbury, England, during the late 1970s before qualifying in Medicine at Dublin's Trinity College in Ireland. Anthony worked as a general surgeon before specialising in

cardiothoracic surgery in the Irish health service. He moved to Quintiles (now IQVIA) for 5 years and then joined Pfizer as Associate Medical Director and Director of Clinical Research in 2003. Working through several successful medical affairs teams at the European level from 2009 with increasing responsibilities, Anthony is currently enjoying his time as medical director within Pfizer's global internal medicine's medical affairs team since 2019.

In 2005, Pharmaceutical Medicine was recognised as a distinct medical specialty by the Irish Department of Health and Children, after a decade of lobbying. As previous vice-chair and current chair of the Association of Pharmaceutical Physicians in Ireland (APPI), Anthony had been advocating for the development of the specialty for its formal accreditation and training since he first joined APPI in 1998.

Through APPI, Anthony has been an active member of the IFAPP Ethics Working Group (WG). He is co-author of the first edition of IFAPP's International Framework of Ethical Conduct for Pharmaceutical Physicians in 2003 and its update in 2017, both published on the [IFAPP website](#).

Currently, the Ethics WG is working on a proposal to the World Medical Association for an amendment to the Declaration of Helsinki, linking it to the Declaration of Taipei. As part of this initiative, the Ethics WG published a pertinent paper titled "[Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics](#)" in October 2020.

For his activities in Ireland and abroad, Anthony has been recognised by IFAPP and IFAPP Academy to be amongst the first cohort of Global Fellows in Medicines Development (GFMD) in March 2020.

Registered as a Specialist in Pharmaceutical Medicine in 2011, Anthony is a member of the Specialist Training Committee for the specialty. When the current National Specialty Director (NSD) Dr Mary Teeling completes her full term of office in 2021, Anthony is due to become NSD, representing the specialty amongst all other medical specialties at the Royal College of Physicians in Ireland. Under the guiding hand of Dr Teeling, the training programme will have its first graduate in 2021, as well as a new trainee starting. The training programme will also undergo a re-approval process as per new regulations.

Living in Clonakilty in West Cork, in his spare time (what's left of it), Anthony likes to go sailing locally with his friends in the Kinsale Yacht Club.

Dr. med. Johanna Schenk FFPM GFMD
Member of the IFAPP Communication Working Group



Thursday, February 25, 2021

COVID-19 PANDEMIC IN JAPAN: FACTS AND EXPECTATIONS

Free Registration

- This webinar is free to everybody.
- Click [here](#) for registration.

PROGRAMME

Chairpersons:

Dr Stewart Geary (Eisai)

Dr Kyoko Imamura (The University of Tokyo)

21:00-21:05	Welcome message from <i>Dr Kazuya Iwamoto</i> , president of JAPhMed
21:05-21:15	Brief overview of COVID-19 pandemic in Japan <i>Prof Kotone Matsuyama</i> , Department of Health Policy and Management, Nippon Medical School
21:15-21:35	Current situation and challenges in COVID-19 treatments and vaccines development <i>Dr Atsushi Tsukamoto</i> , Vice President, New Drug Regulatory Affairs, Daiichi Sankyo
21:35-21:55	Sustainable ethical review and quality assurance in R&D operations in times of COVID-19 <i>Mr Naoki Tsutsumi</i> , Graduate School of Pharmaceutical Sciences, The University of Tokyo
21:55-22:25	Panel discussion
22:25-22:30	Closing message by <i>Dr Marco Romano</i> , IFAPP President

Time Schedule

07:00 - 08:30 AM EST
12:00 - 01:30 PM GMT
01:00 - 02:30 PM CET
09:00 - 10:30 PM JST

IFAPP TODAY

The Global Newsletter on Pharmaceutical Medicine



A SIMeF publication on COVID-19 and clinical research operations

Lessons learned from COVID-19 for clinical research operations in Italy.

All professionals involved in the management of clinical trials are experiencing several difficulties due to the pandemic and the obvious restrictions implemented by university clinics and hospitals for monitoring visits, audits and all additional activities which were usually performed during an on-site visit.

SIMeF, the Italian Association of Pharmaceutical Medicine, in collaboration with clinical investigators, published a constructive proposal for the management of clinical trials during the pandemic.

You can download the publication at this [link](#); enjoy reading it!

THE FLAG

IFAPP secretariat - Leidsestraatweg 41d - 3443 BP Woerden - The Netherlands
Chamber of Commerce 30224375 - VAT number NL817747321B02
Phone: (+31) 6 2291 1039 - e-mail: secretariat@ifapp.org - website: www.ifapp.org.

IFAPP Communication Working Group

Raeefuddin Ahmed, Varvara Baroutsou, Frank Bringstrup, Domenico Criscuolo, Brigitte Franke-Bray, Epainète Gawa, Ilker Gelisen, Ghazaleh Gouya, Kyoko Imamura, Qaddafi Jahangir, Ji-Hyun Kim, Rob van Maanen, Hasan Mahmood, Kotone Matsuyama, Anna Rodet, Johanna Schenk, Peter Stiling, Chinnie Tan, Ajay Tiku.

IFAPP is the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine.

Follow us on:

